CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Medios AG is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Medios AG
Heidestrasse 9
Phone: +49 30232566800p:+49 30232566800 BERLIN, 10557  Germany Ticker: ILM1ILM1
Business Summary
Medios AG, formerly Crevalis Capital AG, is a Germany-based company offering solutions in pharma industry. The Company covers relevant aspects of supply chain like from pharmaceutical supply and manufacture of patient-specific therapies, including blistering and others. It operates in two segments Pharmaceutical supply which focuses on pharmaceutical wholesale with finished specialty pharma (high-priced drugs for rare and chronic diseases) medications including oncology, neurology, autoimmunology, ophthalmology, infectiology, hemophilia along with offering finished medicinal products; Patient-specific therapies focusing on pharmaceutical manufacturing of patient-specific preparations such as Cytostatic infusions, Antibody therapies, Virostatic and antibiotic medications, Parenteral nutrition solutions, Investigational medicinal products are among others. Its products and services include Patient health & protection and procedures & processes for patient care and digitalization of data.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
5122 Drugs, drug proprietaries, and druggists' sundries
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Supervisory Board YannSamson 51 12/5/2014 11/7/2014
Chairman of the Management Board, Chief Executive Officer MatthiasGaertner 57 8/1/2021 11/6/2014
Deputy Chairwoman of the Supervisory Board AnkeNestler 55 6/1/2023 6/10/2021
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Ceban Pharmaceuticals B.V. Kapittelweg 22 BREDA Netherlands

Business Names
Business Name
0QB4
Blisterzentrum Baden-Württemberg GmbH
Ceban Pharmaceuticals B.V.
Cranach Pharma GmbH
ILM1
MIM MONDO IGEL MEDIA AG

General Information
Number of Employees: 1,000 (As of 9/30/2024)
Outstanding Shares: 25,505,723 (As of 9/30/2024)
Shareholders: 1,574
Stock Exchange: ETR
Fax Number: +49 30232566801
Email Address: info@medios.ag


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, January 27, 2025